Immunodetection of NUT Protein: Implementation, Indications, and Results in a Tertiary Reference Center.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
received:
04
04
2023
accepted:
12
10
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
aheadofprint
Résumé
The immunodetection of NUT protein is a reliable tool to identify NUT carcinoma, a rare and still underdiagnosed tumor entity. The technique was implemented in 2017 in our department, a tertiary reference center with a large recruitment in all tumor types, including head and neck and thoracic tumors. We evaluated its use over a 6-year period (2017-2022) to (a) describe the indications for the technique, (b) determine the number of NUT carcinomas detected and confirmed by Fluorescence in situ hybridization, and (c) describe briefly the characteristics of these tumors. Over the study period, 382 NUT immunodetections were performed; the annual number of requests varied from 45 to 83. All 21 pathologists of the department made at least one request (range: 1 to 94; annual mean: 18.2). 54.7% of immunodetections were performed for internal cases, 37% for cases submitted for consultation, and 8.3% for cases submitted for confirmation of a suspected diagnosis. The main indications were poorly differentiated tumors of the head and neck region (39%) and the thorax (19.6%), and difficult-to-classify soft tissue tumors (11.8%). Twelve cases of NUT carcinoma were detected by immunohistochemistry and confirmed by Fluorescence in situ hybridization. Seven were from the head and neck region (4.7% of the tumors tested), 4 from lung or mediastinum (5.3%), 1 from an unknown primary at the time of diagnosis. In conclusion, the implementation of NUT immunodetection in the daily workflow of a pathology department improves the detection of NUT carcinoma. This becomes essential with the emergence of potential targeted therapies.
Identifiants
pubmed: 37972936
doi: 10.1097/PAI.0000000000001172
pii: 00129039-990000000-00146
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
French CA. NUT carcinoma: clinicopathologic features, pathogenesis, and treatment. Pathol Int. 2018;68:583–595.
French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010;203:16–20.
Lauer UM, Hinterleitner M, Horger M, et al. NUT carcinoma—an underdiagnosed malignancy. Front Oncol. 2022;12:914031.
McEvoy CR, Fox SB, Prall OWJ. Emerging entities in NUTM1-rearranged neoplasms. Genes Chromosomes Cancer. 2020;59:375–385.
Davis BN, Karabakhtsian RG, Pettigrew AL, et al. Nuclear protein in testis midline carcinomas: a lethal and underrecognized entity. Arch Pathol Lab Med. 2011;135:1494–1498.
French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304–307.
Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33:984–991.
French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22:4135–4139.
Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol. 2011;5:31–35.
Dickson BC, Sung YS, Rosenblum MK, et al. NUTM1 gene fusions characterize a subset of undifferentiated soft tissue and visceral tumors. Am J Surg Pathol. 2018;42:636–645.
Le Loarer F, Pissaloux D, Watson S, et al. Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol. 2019;43:268–276.
Underwood CIM, Cardona DM, Bentley RC, et al. Epithelioid hyalinizing sarcoma with MGA-NUTM1 fusion. Am J Clin Pathol. 2020;154:859–866.
Van Treeck BJ, Thangaiah JJ, Torres-Mora J, et al. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod Pathol. 2021;34:1547–1557.
McEvoy CR, Holliday H, Thio N, et al. A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Lab Invest. 2021;101:26–37.
Iacobelli JF, Charles AK, Crook M, et al. NUT protein immunoreactivity in ovarian germ cell tumours. Pathology. 2015;47:118–122.
Xu B, Chen JF, Sarungbam J, et al. NUTM1-fusion positive malignant neoplasms of the genitourinary tract: a report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity. Genes Chromosomes Cancer. 2022;61:542–550.
Barletta JA, Gilday SD, Afkhami M, et al. NUTM1-rearranged carcinoma of the thyroid : a distinct subset of NUT carcinoma characterized by frequent NSD3-NUTM1 fusions. Am J Surg Pathol. 2022;46:1706–1715.
Macagno N, Kervarrec T, Sohier P, et al. NUT is a specific immunohistochemical marker for the diagnosis of YAP1-NUTM1-rearranged cutaneous poroid neoplasms. Am J Surg Pathol. 2021;45:1221–1227.
Rubio Gonzalez B, Ortiz MV, Ross DS, et al. Skin adnexal carcinoma with BRD3-NUTM2B fusion. J Cutan Pathol. 2021;48:1508–1513.
Carter T, Crook M, Murch A, et al. Incidence of NUT carcinoma in Western Australia from 1989 to 2014: a review of pediatric and adolescent cases from Perth Children’s Hospital. BMC Cancer. 2021;21:740.
Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol. 2012;36:1216–1221.
Neves-Silva R, Almeida LY, Silveira HA, et al. SMARCB1 (INI-1) and NUT immuno-expression in a large series of head and neck carcinomas in a Brazilian reference center. Head Neck. 2020;42:374–384.
Wang L, Zhu Z, Wang W, et al. Sinonasal NUT carcinoma: a retrospective case series from a single institution. Front Surg. 2023;10:1098704.
Fang W, French CA, Cameron MJ, et al. Clinicopathological significance of NUT rearrangements in poorly differentiated malignant tumors of the upper respiratory tract. Int J Surg Pathol. 2013;21:102–110.
Solomon LW, Magliocca KR, Cohen C, et al. Retrospective analysis of nuclear protein in testis (NUT) midline carcinoma in the upper aerodigestive tract and mediastinum. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:213–220.
Luo W, Stevens TM, Stafford P, et al. NUTM1-rearranged neoplasms—a heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations—an updated review. Curr Oncol. 2021;28:4485–4503.
Nakamura H, Tsuta K, Tsuda H, et al. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. Pathol Res Pract. 2015;211:92–98.
Pezzuto F, Fortarezza F, Mammana M, et al. Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. Histopathology. 2020;77:508–510.
Hung YP, Chen AL, Taylor MS, et al. Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers. Histopathology. 2021;78:896–904.